My ePortfolio Register   

Oestrogen deprivation inffective with chemo for HR/HER positive breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.12.16
Views: 682
Rating:

Dr Mothaffar Rimawi - Baylor College of Medicine, Houston, USA

Dr Rimawi speaks with ecancertv at SABCS 2016 about the results of a trial in which neoadjuvant TCHP chemotherapy was administered alongside oestrogen deprivation therapy in HR/HER positive breast cancer patients.

He considers comments that the chemotherapy regimen seems to blunt the clinical benefit of anti-oestrogens, which may in turn be attributable to the sheer success of chemotherapy, or be influenced by the timing and dosage of the regimens.

These results were first presented in a press conference session, with video available here.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence